HKEX IPO Calendar — Hong Kong New Listings Tracker
Pricing
from $250.00 / 1,000 ipo records
Track upcoming and recent Hong Kong IPOs from HKEX. Get listing dates, offer prices, sponsors, sectors — straight from the source. Useful for investors, IPO traders, allocators, journalists.
Which slice of the Hong Kong Stock Exchange (HKEX) IPO universe to return. 'upcoming' = announced prospectuses filed with the HKEX listing committee but not yet listed (forward calendar — typically 10-30 active book-builds at any time, including A+H secondaries by mainland China issuers and Chapter 18C Specialist Technology Companies regime listings). 'recent' = past N days of completed IPOs (priced + first-day-of-trading deals) with first-day pop and current return. 'both' (default) = upcoming + recent in one pull, sorted with Upcoming first then most-recent listings.
How many days of completed HKEX IPOs to include when mode is 'recent' or 'both'. Default 30 days returns the most-recent month of pricing activity — typically 3-8 deals on Main Board plus 1-3 GEM listings in an active month. HKEX prices roughly 60-100 IPOs/year across Main Board + GEM; 90 days (~quarter) is the practical upper bound for institutional desk dashboards. Set higher (e.g. 365) for full-year vintage studies, post-IPO return cohort analysis or sponsor / underwriter league-table research.
How many days of forward HKEX IPO calendar to include when mode is 'upcoming' or 'both'. Default 30 days returns the active book-build pipeline (deals with prospectuses live on the HKEX listing-committee hearing schedule). 60-90 days extends to the medium-term pipeline (deals with PHIP / Post-Hearing Information Pack filed but listing date not yet fixed). 180+ days surfaces the soft pipeline (rumored / sponsor-mandated but not yet PHIP-filed). HKEX has been the world's #1 IPO venue by proceeds in 5 of the last 15 years.
Filter by HKEX board. 'Main Board' = senior board with quantitative entry tests (HK$50M profit test, HK$500M market-cap-revenue test, or HK$4bn market-cap-revenue-cashflow test); home to all the China large-cap A+H secondaries, BABA-class weighted-voting-rights listings (Chapter 8A), and Chapter 18A pre-revenue biotech listings. 'GEM' = growth-board (Growth Enterprise Market) — relaunched 2024 with revised rules; targets SMEs. 'all' returns both boards.
Filter by sector classification. HKEX IPO sector mix has shifted dramatically since 2018: pre-2018 it was Financials (Chinese bank A+H, insurance), 2018-2021 was Technology (BABA, Meituan, JD.com secondaries, NetEase secondary, Bilibili), 2022-2024 was Healthcare (Chapter 18A pre-revenue biotech wave — InnoCare, Cansino, Innovent), 2024-2026 is Consumer Discretionary (HK consumer brand re-listings — Mixue Bingcheng, Chabaidao, Bawang Chaji, Laopu Gold) and a new Specialist Technology Companies (Chapter 18C) AI/semiconductor wave (Black Sesame, WeRide aspirations). 'all' = no filter.
Lower bound on gross IPO proceeds in HKD millions. Use to filter out micro-cap GEM offerings. Typical thresholds: '50' = small Main Board, '500' = sizeable Main Board, '1000' = institutional-grade (HK$1bn+), '5000' = mega-deal (Midea Group HK$31bn, Mixue Bingcheng HK$3.4bn, S.F. Holding HK$5.7bn, Horizon Robotics HK$5.4bn class). Leave 0 for no lower bound. 1 HKD ≈ 0.128 USD.
Hard cap on total HKEX IPO records returned (1-200). Each IPO is one dataset row. Premium pricing applies per row — HKEX IPO data is institutional intel (Bloomberg HK IPO / Refinitiv / Renaissance Capital equivalents cost USD 2,000+/seat/month). HKEX prices ~30-100 IPOs/year so most useful runs are limit=20-100. Records are sorted Upcoming-first by listing date ascending, then completed-IPOs by ipo_date descending.
